Aktualności
FDA: Questions and Answers on Current Good Manufacturing Practices (cGMP) for Drugs
03.07.2009
FDA developed question and answer resource on Current Good Manufacturing Practices. ...
Polish Ministry of Health: Regulation project on the Good Manufacturing Practices
03.07.2009
Polish Ministry of Health: Regulation project on the Good Manufacturing Practices ...
EMEA: Overview of status of HMPC assessment work - priority list
30.06.2009
Overview of status of HMPC assessment work - priority list ...
EMEA: Qualification of novel methodologies for drug development: Guidance to applicants
30.06.2009
As the scientific knowledge and the intended use of a new method may change in line with the generation of additional data the EMEA qualification process may encompass an ongoing interaction
...
EMEA: Dossier requirements
30.06.2009
It is presented dossier requirements for Post-authorisation submissions in the centralised procedure ...
MHRA: MLX 357 - Outcome of consultation on measures to strengthen the medicines’ supply chain and reduce risk from counterfeit medicines
30.06.2009
This consultation sought your views on a number of proposals to improve the operation of the medicines’ supply chain in the UK. It also sought views on European Commission proposals to amend
...
FDA: Questions and Answers on Current Good Manufacturing Practices (cGMP) for Drugs
30.06.2009
As part of the cGMP initiative announced in August of 2002, and to help FDA be more transparent with cGMP policy, FDA has developed this question and answer resource on Current Good Manufacturing
...
FDA: Updating Labeling for Susceptibility Test Information in Systemic Antibacterial Drug Products and Antimicrobial Susceptibility Testing Devices
30.06.2009
The purpose of this guidance is to inform industry of how the FDA intends to comply with section 1111 of the Food and Drug Administration Amendments Act (FDAAA), which requires FDA to identify and
...
EMEA: Reflection paper Non-clinical and clinical development of similar medicinal products containing recombinant interferon alpha
29.06.2009
This product specific reflection paper presents the current view of the CHMP on the non-clinical and clinical data for demonstration of comparability of two recombinant, non-pegylated, Interferon
...
EMEA: ICH E 16 Note for guidance on genomic biomarkers related to drug response: context, structure and format of qualification submissions
29.06.2009
The guideline describes recommendations regarding context, structure, and format of regulatory submissions for qualification of genomic biomarkers, as defined in ICH E151. Biomarker qualification
...
